Skip to main content

Table 3 Outcomes of patients receiving intravenous PMB

From: Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study

Outcomes n (%)
Bacteria eradication rate, n (%) 66 (77.65)
Treatment duration, median (IQR) 11 (9, 13)
Adverse events, n (%) 16 (16)
 Nephrotoxicity 7 (7)
 Neurotoxicity 6 (6)
 Skin hyperpigmentation 3 (3)
 Eosinophil increase 7 (7)
ICU mortality, n (%) 12 (12)
Hospital mortality, n (%) 15 (15)
28-day mortality, n (%) 40 (40)